Shilpa Medicare Limited

NSEI:SHILPAMED Rapport sur les actions

Capitalisation boursière : ₹77.5b

Shilpa Medicare Croissance future

Future contrôle des critères 5/6

Shilpa Medicare devrait augmenter ses bénéfices et son chiffre d'affaires de 77.1% et de 29.2% par an respectivement. Le BPA devrait croître de de 76.5% par an. Le rendement des capitaux propres devrait être 14.1% dans 3 ans.

Informations clés

77.1%

Taux de croissance des bénéfices

76.5%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices17.9%
Taux de croissance des recettes29.2%
Rendement futur des capitaux propres14.1%
Couverture par les analystes

Low

Dernière mise à jour18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Sep 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

Jul 05
Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Apr 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Feb 21
Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Jan 02
Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Jul 17
These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Mar 17
Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Sep 07
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Aug 14
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Jan 27
Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Sep 21
Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jun 17
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 07
Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Feb 20
Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jan 26
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Prévisions de croissance des bénéfices et des revenus

NSEI:SHILPAMED - Estimations futures des analystes et données financières antérieures (INR Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
3/31/202726,7206,215N/A5,7261
3/31/202617,0943,648N/A3,5052
3/31/202514,4131,3403542,7041
9/30/202412,163611-4521,500N/A
6/30/202411,839448N/AN/AN/A
3/31/202411,531319-4921,353N/A
12/31/202311,248-7N/AN/AN/A
9/30/202311,008-119-302,523N/A
6/30/202310,491-321N/AN/AN/A
3/31/202310,517-325-4671,799N/A
12/31/202211,28651N/AN/AN/A
9/30/202211,384213-1,6201,651N/A
6/30/202211,693599N/AN/AN/A
3/31/202211,469607-2,2671,051N/A
12/31/202110,135395N/AN/AN/A
9/30/20219,324376-2,589478N/A
6/30/20219,156631N/AN/AN/A
3/31/20219,0161,478-3,073469N/A
12/31/20209,1351,739N/AN/AN/A
9/30/20209,5912,213-2,704793N/A
6/30/20209,6982,267N/AN/AN/A
3/31/20209,0821,562-2,2491,244N/A
12/31/20198,8761,455N/AN/AN/A
9/30/20198,2411,029-3,065819N/A
6/30/20196,962944N/AN/AN/A
3/31/20197,3371,123-1,5321,468N/A
12/31/20187,6931,193N/AN/AN/A
9/30/20187,8141,281N/AN/AN/A
6/30/20188,2111,167N/AN/AN/A
3/31/20187,8941,052N/A449N/A
12/31/20177,7561,133N/AN/AN/A
9/30/20177,7311,149N/AN/AN/A
6/30/20177,7871,190N/AN/AN/A
3/31/20177,7951,076N/A375N/A
12/31/20167,5651,048N/AN/AN/A
9/30/20167,7351,153N/AN/AN/A
6/30/20167,3691,024N/AN/AN/A
3/31/20167,1661,083N/A1,287N/A
12/31/20156,867886N/AN/AN/A
9/30/20156,430776N/AN/AN/A
6/30/20156,234728N/AN/AN/A
3/31/20156,138737N/A688N/A
12/31/20146,145731N/AN/AN/A
9/30/20146,143798N/AN/AN/A
6/30/20145,966787N/AN/AN/A
3/31/20145,714757N/A700N/A
12/31/20135,025664N/AN/AN/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de SHILPAMED ( 77.1% par an) est supérieure au taux d'épargne ( 6.7% ).

Bénéfices vs marché: Les bénéfices de SHILPAMED ( 77.1% par an) devraient croître plus rapidement que le marché Indian ( 17.9% par an).

Croissance élevée des bénéfices: Les bénéfices de SHILPAMED devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de SHILPAMED ( 29.2% par an) devrait croître plus rapidement que le marché Indian ( 10.5% par an).

Croissance élevée des revenus: Le chiffre d'affaires de SHILPAMED ( 29.2% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de SHILPAMED devrait être faible dans 3 ans ( 14.1 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y